Virkningen blev hovedsagelig bedømt på den “ mediane progressionsfrie overlevelse ” (den tid, der går inden 50% af patienterne har oplevet sygdomsforværring eller er døde).
The main measure of effectiveness was the ‘ median progression-free survival’ (the length of time until 50% of the patients had experienced a worsening of their disease or had died).